Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment

References

• Baker WL, Talati R, White CM, Coleman CI. 2010. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 87:98–107.
   PubMed Web of Science ®Google Scholar
• Baptista T, Kin NM, Beaulieu S. 2004. Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions. Clin Pharmacokinet 43:1–15.
   PubMedGoogle Scholar
• Brown S. 1997. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 171:502–508.
   PubMed Web of Science ®Google Scholar
• Colton CW, Manderscheid RW. 2006. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3: 1–14.
   Google Scholar
• De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, et al. 2011. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10:138–151.
   PubMed Web of Science ®Google Scholar
• De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. 2011. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10:52–77.
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. 2009. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24:412–424.
   PubMed Web of Science ®Google Scholar
• Elliot W, Meyer PM. 2007. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001). JAMA 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. 2007. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 28:2375–2414.
   PubMed Web of Science ®Google Scholar
• Gupta K, Gupta S. 2002. Undertreatment of hypertension: a dozen reasons. Arch Intern Med 162:2246–2247.
   PubMedGoogle Scholar
• Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. 1990. Cardiovascular risk factors in confirmed prediabetic inidividuals. JAMA 263:2893–2898.
   PubMed Web of Science ®Google Scholar
• Heilä H, Haukka J, Suvisaari J, Lönnqvist J. 2005. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 35:725–732.
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Hennekens AR, Hollar D, Casey DE. 2005. Schizophrenia and increased risk of cardiovascular disease. Am Heart J 150:1115–1121.
   PubMed Web of Science ®Google Scholar
• Killbourne AM, Welsh D, McCarthy JF, Post EP, Blow FC. 2008. Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders. J Gen Intern Med 23:1628–1633.
   PubMedGoogle Scholar
• Koh KK, Sakuma I, Quon MJ. 2011. Differential metabolic effects of distinct statins. Atherosclerosis 215:1–8.
   PubMed Web of Science ®Google Scholar
• Laursen TM. 2011. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizoprh Res 131:101–104.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Vestergaard M. 2012. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 25:83–88.
   PubMed Web of Science ®Google Scholar
• Lawrence D, Kisely S, Pais J. 2010. The epidemiology of excess mortality in people with mental illness. Can J Psychiatry 55: 752–760.
   PubMed Web of Science ®Google Scholar
• L’Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. 2007. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 68:1510–1516.
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. 2012. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 42: 125–147.
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. 2011. Prevalance of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders. A systematic review and meta-analysis. Schizophr Bull. Epub ahead of print 29 December 2011; doi:10.1093/schbul/sbr148.
   PubMedGoogle Scholar
• Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. 2006. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86:15–22.
   PubMed Web of Science ®Google Scholar
• Ösby U, Correia N, Brandt L, Ekbom A, Sparén P. 2000. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 45:21–28.
   PubMed Web of Science ®Google Scholar
• Pearson TA. 2000. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 74:S23–S28.
   PubMedGoogle Scholar
• Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. 2007. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88–136.
   PubMed Web of Science ®Google Scholar
• Saarni SE, Saarni SI, Fogelholm M, Heliövaara M, Perälä J, Suvisaari J, Lönnqvist J. 2009. Body composition in psychotic disorders: a general population survey. Psychol Med 39:801–810.
   PubMedGoogle Scholar
• Saddichha S, Manjunatha N, Ameen S, Akhtar S. 2008. Diabetes and schizophrenia – effect of disease or drug? Results from a randomized double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 117:342–347.
   PubMedGoogle Scholar
• Schorr SG, Slooff CJ, Burggeman R, Taxis K. 2009. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 43: 1106–1111.
   PubMed Web of Science ®Google Scholar
• Scott D, Happell B. 2011. The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. Issues Ment Helath Nurs 32:589–597.
   PubMedGoogle Scholar
• Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. 2001. Hypothesis: β-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37:250–254.
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusaraisin N. 2007. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 7:14–19.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Mignon L, Meyer JM. 2009. Which comes first: atypical antipsychotic treatment of cardiometabolic risk?Acta Psychiatr Scand 119:171–179.
   PubMed Web of Science ®Google Scholar
• Taxis K, Schorr S, Fouchier M, Slooff C, Bruggeman R. 2008. Is it appropriate to use cardiovascular risk scores in patients with psychotic disorders?Schizophr Res 102:169.
   Google Scholar
• Taylor F, Ward K, Moore THM, Burke M, Davey Smith G, Casas JP, et al. 2011. Statins for the primary prevention of cardiovascular disease (Review). Cochrane Database Syst Rev 19:CD004816.
   Google Scholar
• Tiihonen J, Lönnqvist J, Wahlbeck K, Kalukka T, Niskanen L, Tanskanen A, Haukka J. 2009. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11study). Lancet 374:620–627.
   PubMed Web of Science ®Google Scholar
• Tonstad S, Rosvold EO, Furu K, Skurtveit S. 2004. Undertreatment and overtreatment with statins: the Oslo Health Study 2000–2001. J Intern Med 255:494–502.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Knapen J, Probst M, Winkel R, Deckx S, Maurissen K, et al. 2010. Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res 177:271–279.
   PubMed Web of Science ®Google Scholar
• Van Der Gaag RJ. 2011. Mental health ‘cure and care’ in the Netherlands: risks and opportunities. Int Rev Psychiatry 23:113–117.
   PubMed Web of Science ®Google Scholar
• Van Hout BA, Simoons ML. 2001. Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat?Eur Heart J 22: 751–761.
   PubMed Web of Science ®Google Scholar
• Verhaeghe N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L. 2011. Effectiveness and cost-effectiveness of life-style interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act 8:28–39.
   PubMed Web of Science ®Google Scholar
• Vreeland B. 2007. Treatment decisions in major mental illness: weighing the outcomes. J Clin Psychiatry 68:5–11.
   PubMed Web of Science ®Google Scholar
• Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. 2007. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11: 1–160.
   Web of Science ®Google Scholar
• Webber MA, Mahmud W, Lightfoot JD, Shekhar A. 2004. Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol 18:432–434.
   PubMed Web of Science ®Google Scholar
• Weiss AP, Henderson DC, Weilburg JG, Goff DC, Meigs JB, Cagliero E, Grant RW. 2006. Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatr Serv 57:1145–1152.
   PubMed Web of Science ®Google Scholar
• Winer N, Sowers JR. 2004. Epidemiology of diabetes. J Clin Pharmacol 44:397–405.
   PubMed Web of Science ®Google Scholar